Dr. Vivek Subbiah, MD

Dr. Subbiah practices at Nashville Oncology Associates in Brentwood, Tennessee.

Dr. Subbiah's NPI, 1174726384, was assigned on June 6, 2007. Dr. Subbiah holds Texas license N6693.

Dr. Subbiah's primary practice is Nashville Oncology Associates, at 201 Franklin Rd, Brentwood, TN 37027 in Williamson County. The practice phone is (615) 329-7640.

Dr. Subbiah's primary practice is Nashville Oncology Associates in Brentwood, Tennessee. Dr. Subbiah is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is Nashville Oncology Associates, PC. Dmand AI also links Dr. Subbiah to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Subbiah practices, 2 sites in all. Vendor and product names are available with a free account.

Pediatric hematology-oncology is Dr. Subbiah's primary specialty in the NPI Registry, under taxonomy code 2080P0207X. Dr. Subbiah is board certified in medical oncology by the American Board of Internal Medicine. Dr. Subbiah is licensed in Texas.

CMS data shows 646 Medicare services from Dr. Subbiah across 9 procedure codes in 2024, for 67 Medicare patients. Medicare paid $17,640 for them. Every service was in an office.

CMS counts 67 Medicare patients who saw Dr. Subbiah in 2024. The largest group is 65 to 74, with 43 patients. 70% of them have high blood pressure, and 64% have high cholesterol. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Subbiah's median patient age at 62, with 68% women.

In 2024, Dr. Subbiah wrote 43 Medicare Part D claims for 16 patients. 84% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $148 in total drug cost. In 2019, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Subbiah for performance year 2024, reported as part of a group. Dr. Subbiah accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Subbiah as offering telehealth.

Dmand AI links 417 papers to Dr. Subbiah, published from 2010 to 2025. 2023 was the busiest year, with 46. The most frequent topics are Precision Medicine, Lung Neoplasms and Protein Kinase Inhibitors. Dr. Subbiah has published most often in Clin Cancer Res. Dr. Subbiah's most frequent co-authors are Daniel D. Karp, MD, Sarina Anne Piha-Paul, MD and Aung Naing, MD.

Dmand AI links Dr. Subbiah to 10 clinical trials, 6 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Neoplasm Metastasis, Neoplastic Processes and Brain Neoplasms. M.D. Anderson Cancer Center sponsors the most, 2.

CMS Open Payments shows 194 general payments to Dr. Subbiah from 38 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Incyte Corporation paid the most, $34,973. It also lists 23 research payments totaling $30,269 from 2016 to 2025.